Contrasting Silo Pharma (NASDAQ:SILO) and InterCure (NASDAQ:INCR)

InterCure (NASDAQ:INCR) and Silo Pharma (NASDAQ:SILO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Institutional & Insider Ownership

8.3% of InterCure shares are held by institutional investors. Comparatively, 5.6% of Silo Pharma shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 3.6% of Silo Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares InterCure and Silo Pharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47 million	0.73	-$10.37 million	$0.15	35.00
Silo Pharma	$70,000.00	48.84	-$4.23 million	($4.36)	-0.49

Silo Pharma has lower revenue, but higher earnings than InterCure. Silo Pharma is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

InterCure has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for InterCure and Silo Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1	0	0	0	1.00
Silo Pharma	1	0	0	0	1.00

Profitability

This table compares InterCure and Silo Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Silo Pharma	-6,726.39%	-81.75%	-66.35%

Summary

InterCure beats Silo Pharma on 8 of the 11 factors compared between the two stocks.

About InterCure

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

About Silo Pharma

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.